Pharmacore raises undisclosed round for AI pharmacist-review tool
What's the deal? PharmacoreDealroom has a profile for this one. Try Dealroom →, an Irvine, California startup, has secured funding to expand adoption of its clinical decision support software for medication regimen reviews (MRRs) in long-term care. The investment will fund product development and onboarding for consultant pharmacists and pharmacy groups. The company did not disclose the amount or its investors.
What's the endgame? Pharmacore pulls medication administration records, physician orders, and lab results into one review workflow, flags potential drug issues, and drafts recommendations and reports. The pharmacist stays in control, deciding whether to accept, edit, or reject each suggestion.
Why now? Federal rules require a pharmacist to review each nursing-home resident's drug regimen at least monthly, a task that involves gathering records, running repetitive checks, and preparing documentation. Pharmacore aims to cut that manual load. "Our aim is simple: give clinical judgment its time back," said co-founder and chief executive officer Dave Robbins.
Built with practicing pharmacists, the platform lets users compare system-generated suggestions with their own findings before completing a review. "We built Pharmacore around the work pharmacists do every month," said co-founder Tim Merritt, a doctor of pharmacy. The company is offering free trials to consultant pharmacists and will demonstrate the product at the American Society of Consultant Pharmacists 2026 Annual Meeting from October 29 to November 1 in National Harbor, Maryland.
What could go wrong? The announcement discloses no funding figure, named investors, or customers, and the company — founded in 2026 — appears to be at a very early, pre-seed stage. Independent searches have not corroborated adoption at scale or evidence that the software improves clinical outcomes.
The signal: Pharmacore represents a focused bet on workflow automation inside the long-term care pharmacy market, targeting a mandatory, repetitive clinical process rather than drug discovery. Its significance will hinge on disclosed pilots, customer uptake, and proof that pharmacist oversight stays effective as more of the work is automated.
Read more: pr.lakeoconeebreeze.net
Image credit: NavyMedicine
